MINK THERAPEUTICS INC
Biotech · Public
agenT-797, an off-the-shelf allogeneic cellular immunotherapy composed of invariant Natural Killer T (iNKT) cells for hematopoietic stem cell transplantation
- Grants
- $613K
- 2 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 30
- 4 granted · 26 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓202420252026
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · Developing allogeneic iNKT cell adoptive therapy to improve outcomes for HSCT indications | $306,500 | |
| Federal grant | Department of Health and Human Services · Phase I · Developing allogeneic iNKT cell adoptive therapy to improve outcomes for HSCT indications | $306,500 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1630 | Atum Works | — | — |
| 1631 | Quell Therapeutics | — | — |
| 1632 | Inipharm | — | — |
| 1633 | MINK THERAPEUTICS INC | — | — |
| 1634 | MANHATTAN BIOSOLUTIONS, LLC | — | — |
| 1635 | Find Genomics Inc. | — | — |
| 1636 | Amplifier Therapeutics | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- T Cell Receptors That Bind To Mixed Lineage Leukemia (mll)-specific Phosphopeptides And Methods Of Use Thereofapplication
- Invariant Natural Killer T Cells For Treating Acute Respiratory Distress Syndrome (ards)application
- B-cell Maturation Antigen (bcma) Chimeric Antigen Receptor Invariant Natural Killer T Cells And Uses Thereofapplication
- T Cell Receptors That Bind To Mixed Lineage Leukemia (mll)-specific Phosphopeptides And Methods Of Use Thereofgranted
- T Cell Receptors That Bind To NY-ESO-1 And Methods Of Use Thereofapplication
- Engineered Host Cells And Methods Of Use Thereofgranted
- T Cell Receptors That Bind To Mixed Lineage Leukemia (mll)-specific Phosphopeptides And Methods Of Use Thereofgranted
- T Cell Receptors That Bind To NY-ESO-1 And Methods Of Use Thereofgranted
- B-cell Maturation Antigen (bcma) Chimeric Antigen Receptor Invariant Natural Killer T Cells And Uses Thereofapplication
- Novel Invariant Natural Killer T Cells And T Cell Engager Compositions And Methods Of Use Thereofapplication
- Fibroblast Activation Protein (fap) Car-invariant Natural Killer T Cells And Uses Thereofapplication
- Novel T Cell Receptors That Bind To Preferentially Expressed Antigen In Melanoma (prame) And Methods Of Use Thereofapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.